We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-18.74%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$404M
AUM Growth
-$183M
Cap. Flow
-$944K
Cap. Flow %
-0.23%
Top 10 Hldgs %
67.69%
Holding
33
New
3
Increased
15
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$10.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.76M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$7.53M
4
BPMC
Blueprint Medicines
BPMC
+$6.28M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$5.48M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$13.3M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$11.6M
4
CTMX icon
CytomX Therapeutics
CTMX
+$37.6K
5
CALA
Calithera Biosciences, Inc
CALA
+$28.3K

Sector Composition

Rank Sector Weight
1 Healthcare 64.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.14B
$1.01M 0.25%
52,814
– –
CALA
27
DELISTED
Calithera Biosciences, Inc
CALA
$925K 0.23%
8,145
-250
-3% -$28.3K
VXRT
28
DELISTED
Vaxart
VXRT
$526K 0.13%
31,889
– –
RXDX
29
DELISTED
Ignyta, Inc.
RXDX
$339K 0.08%
+50,000
New +$412K
NRX
30
DELISTED
NEPHROGENEX INC COM
NRX
$184K 0.05%
392,156
– –
FPRX
31
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-300,000
Closed -$12.4M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2016 Portfolio in Review

As of Q1 2016, BVF Inc held 33 positions worth $404M, down 31% from $587M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

BVF Inc's Q1 2016 filing shows 3 new, 15 increased, 4 reduced and 1 closed positions. Its largest new stake was Esperion Therapeutics: 606,801 shares worth $10.3M. The largest sale was Loxo Oncology, Inc, an estimated $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 65% a quarter earlier.

  • BVF Inc's largest Q1 2016 buy was Esperion Therapeutics: 606,801 shares worth $10.3M.
  • BVF Inc added most to Cytokinetics in Q1 2016, an estimated $10.4M increase.
  • BVF Inc's biggest Q1 2016 reduction was Loxo Oncology, Inc, cutting an estimated $13.3M.
  • BVF Inc fully exited Five Prime Therapeutics, Inc. in Q1 2016, selling an estimated $12.4M.
  • BVF Inc's ten largest holdings make up 68% of its $404M portfolio in Q1 2016.
  • BVF Inc opened 3 new positions and closed 1 in Q1 2016.
  • BVF Inc's portfolio value fell 31% quarter-over-quarter to $404M.

Based on BVF Inc's 13F filing for Q1 2016, filed 16 May 2016.